Skip to Content
Merck
All Photos(1)

Key Documents

Safety Information

HSTCMAG28SPMX13

Millipore

MILLIPLEX® Human High Sensitivity T Cell Panel Premixed 13-plex - Immunology Multiplex Assay

Simultaneous analyze low levels of cytokine and chemokine biomarker with the High Sensitivity Bead-Based Multiplex Assays using the Luminex technology, in human serum, plasma and cell culture samples.

Synonym(s):

Human high-sensitivity cytokine multiplex kit, Luminex® human high-sensitivity cytokine immunoassay, Millipore human high-sensitivity cytokine panel

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.47

Quality Level

species reactivity

human

manufacturer/tradename

Milliplex®

assay range

accuracy: 98-107%
sensitivity: 0.11-8.17 pg/mL
(Overnight Incubation minDC)

standard curve range: 0.18-750 pg/mL
(IL-6)

standard curve range: 0.24-1,000 pg/mL
(IL-13)

standard curve range: 0.31-1,250 pg/mL
(IL-8)

standard curve range: 0.37-1,500 pg/mL
(IL-7)

standard curve range: 0.45-1,750 pg/mL
(TNFα)

standard curve range: 0.49-2,000 pg/mL
(IL-1β)

standard curve range: 0.49-2,000 pg/mL
(IL-12 (p70))

standard curve range: 0.49-2,000 pg/mL
(IL-2)

standard curve range: 0.49-2,000 pg/mL
(IL-5)

standard curve range: 0.61-2,500 pg/mL
(IFNγ)

standard curve range: 1.22-5,000 pg/mL
(GM-CSF)

standard curve range: 1.46-6,000 pg/mL
(IL-10)

standard curve range: 1.83-7,500 pg/mL
(IL-4)

inter-assay cv: <15%
intra-assay cv: <10%

technique(s)

multiplexing: suitable

compatibility

configured for Premixed

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

General description

Cytokines are immunomodulatory polypeptides that play key roles in both adaptive and innate immune responses. A generic term, “cytokines” includes myokines (produced by muscle cells), lymphokines (produced by activated Th cells), interleukins (acting as mediators between T cells) and chemokines (responsible for T-cell migration). One of the regulatory mechanisms of the immune system, cytokines act at the recognition, activation, or effector phases of an immune response, modulating the development and functional activities of the subtypes of T cells, B cells and myeloid cells. Consequently, research involving cytokines plays a significant role in achieving a deeper understanding of the immune system and its multi-faceted response to most antigens, especially those responses that make up the inflammatory process. Low levels of inflammation are involved in many clinical and sub-clinical disease states, such as autoimmune disease, cardiovascular disease, diabetes, neurological disorders, and cancer. Measuring picogram levels of cytokines, therefore, is critical for understanding the pathogenesis of these diseases.

The MILLIPLEX® Human High Sensitivity T Cell Magnetic Bead Panel is to be used for the simultaneous quantification of any or all of the following analytes in human plasma, serum, and cell/tissue culture supernatant samples: Fractalkine, GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, IL-21, IL-23, ITAC, MIP-1α, MIP-1β, MIP-3α
and TNFα.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Cytokines/Chemokines

Specificity

Cross Reactivty
There is no detectable cross-reactivity within the panel.

Application

  • Analytes: GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, TNF-α
  • Because there are unique features concerning sample prep and assay set-up, please read the entire protocol before running the assay.
  • Recommended Sample type: Serum, plasma or tissue/cell lysate and culture supernatant
  • Assay Run Time: Overnight
  • Research Category: Inflammation & Immunology
  • Research Sub-Category: Immune Response, Metabolic Disorders, Chronic Inflammatory Disease, Cardiovascular Disease, Neuroscience

Linkage

Replaces: HSCYMAG60SPMX13

Storage and Stability

Recommended storage for kit components is 2 - 8°C.

Other Notes

Please contact Technical Service for linearity of dilution.
Sensitivity: Please see kit protocol for individual assay sensitivities.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Target Organs

Respiratory Tract

Storage Class Code

10 - Combustible liquids


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

HSTCMAG28SPMX13:


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tatum Sevenoaks et al.
Brain, behavior, and immunity, 91, 65-73 (2020-08-30)
HIV-exposed uninfected (HEU) children may have altered immune regulation and poorer neurodevelopment outcomes compared to their HIV-unexposed (HU) counterparts. However, studies investigating the association of maternal and infant inflammation with neurodevelopment in HEU children are limited and longitudinal data are
Pavlos Msaouel et al.
Oncotarget, 8(26), 42149-42158 (2017-02-09)
No biomarkers are available to predict relative clinical benefit from targeted therapies in patients with non-clear cell renal cell carcinoma (nccRCC). To identify candidate predictive markers, we investigated a set of cytokines and angiogenic factors (CAFs) in previously untreated patients
Emily Han-Chung Hsiue et al.
Science (New York, N.Y.), 371(6533) (2021-03-03)
TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53, are not yet available. Here, we describe the identification of an antibody highly specific to the most
Giedre Krenciute et al.
Cancer immunology research, 5(7), 571-581 (2017-05-28)
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and is virtually incurable with conventional therapies. Immunotherapy with T cells expressing GBM-specific chimeric antigen receptors (CAR) is an attractive approach to improve outcomes. Although CAR T cells targeting
Amparo Alfonso et al.
Scientific reports, 9(1), 10576-10576 (2019-07-25)
Cyclophilins (Cyps) are ubiquitous proteins that belong to the immunophilins family consistently associated with inflammatory and cardiovascular diseases. While levels of CypA have been extensively studied, less data are available for other Cyps. The purpose of this case-control study was

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service